Opinions Lou Schizas
Aptose BiosciencesAPS.TODON'T BUYDec 09, 2003
Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.
Lou SchizasUnknown
$1.04
Stock price when the opinion was issued
$2.33
As of Jun 09, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
SELL
At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.
biotechnologypharmaceutical
BUY
A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.
Robert FloydOwned
biotechnologypharmaceutical
BUY
One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.
Robert FloydOwned
biotechnologypharmaceutical
DON'T BUY
Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.
Robert FloydOwned
biotechnologypharmaceutical
WEAK BUY
Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.
Hugh McCauleyOwned
biotechnologypharmaceutical
BUY
A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.
Robert FloydOwned
biotechnologypharmaceutical
BUY
Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.
Robert FloydOwned
biotechnologypharmaceutical
BUY
Just did a financing to extend development on new products. Sees further improvement.
Robert FloydOwned
biotechnologypharmaceutical
